Immutep Limited

    Jurisdiction
    Australia
    LEI
    529900OL6C5CY5P8BH38
    ISIN
    US45257L1089 (IMMP)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7

    Profile

    Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. Read full profile

    Fundamentals

    Net revenue
    €4.94M
    Gross margin
    -669.6%
    EBIT
    -€90.57M
    EBIT margin
    -1,835.2%
    Net income
    -€47.26M
    Net margin
    -957.6%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €4.57M -7.5% -€33.39M -29.4%
    €2.38M -47.9% -€29.31M -12.2%
    €1.47M -38.4% -€32.00M +9.2%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Earnings Calls

    Latest earnings call: August 5, 2013 (Q4 2013)

    Add to watchlist

    Notifications